Publication Date
1-8-2024
Journal
Biomedicines
Abstract
BACKGROUND: Loss of substantia nigra dopaminergic cells and alpha-synuclein (α-syn)-rich intraneuronal deposits within the central nervous system are key hallmarks of Parkinson's disease (PD). Levodopa (L-DOPA) is the current gold-standard treatment for PD. This study aimed to evaluate
METHODS: Anaesthetised 6-month-old mice expressing human A53T alpha-synuclein (HOM) and wildtype (WT) control littermates were intraperitoneally given 20 mg/kg L-DOPA (50 mg levodopa, 2.5 mg benserazide) or vehicle saline (
RESULTS: We found that photoreceptor (a-wave) and bipolar cell (b-wave) ERG responses (
CONCLUSIONS: These findings deepen our understanding of dopamine and alpha-synuclein interactions in the retina and provide a high-throughput preclinical framework, primed for translation, through which novel therapeutic compounds can be objectively screened and assessed for fast-tracking PD drug discovery.
Keywords
A53T mice, levodopa, Parkinson’s disease, electroretinography, optical coherence tomography, amacrine cells, immunohistochemistry
Comments
Supplementary Materials
PMID: 38255235